FLT3 inhibitors in acute myeloid leukemia
2018; BioMed Central; Volume: 11; Issue: 1 Linguagem: Inglês
10.1186/s13045-018-0675-4
ISSN1756-8722
AutoresMei‐Hwan Wu, Chuntuan Li, Xiongpeng Zhu,
Tópico(s)Protein Degradation and Inhibitors
ResumoFLT3 mutations are one of the most common findings in acute myeloid leukemia (AML). FLT3 inhibitors have been in active clinical development. Midostaurin as the first-in-class FLT3 inhibitor has been approved for treatment of patients with FLT3-mutated AML. In this review, we summarized the preclinical and clinical studies on new FLT3 inhibitors, including sorafenib, lestaurtinib, sunitinib, tandutinib, quizartinib, midostaurin, gilteritinib, crenolanib, cabozantinib, Sel24-B489, G-749, AMG 925, TTT-3002, and FF-10101. New generation FLT3 inhibitors and combination therapies may overcome resistance to first-generation agents.
Referência(s)